{"organizations": [], "uuid": "67cf29d136fd4a882cb351fbf71ff20b8c6ba2b7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-acerus-licenses-natesto-in-19-cent/brief-acerus-licenses-natesto-in-19-central-and-latin-american-countries-idUSFWN1RQ01Y", "country": "US", "domain_rank": 408, "title": "BRIEF-Acerus Licenses Natesto In 19 Central And Latin American Countries", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-13T14:14:00.000+03:00", "replies_count": 0, "uuid": "67cf29d136fd4a882cb351fbf71ff20b8c6ba2b7"}, "author": "", "url": "https://www.reuters.com/article/brief-acerus-licenses-natesto-in-19-cent/brief-acerus-licenses-natesto-in-19-central-and-latin-american-countries-idUSFWN1RQ01Y", "ord_in_thread": 0, "title": "BRIEF-Acerus Licenses Natesto In 19 Central And Latin American Countries", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "acerus pharmaceuticals corporation", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 16 AM / Updated 7 minutes ago BRIEF-Acerus Licenses Natesto In 19 Central And Latin American Countries Reuters Staff \nApril 13 (Reuters) - Acerus Pharmaceuticals Corporation : \n* ACERUS ANNOUNCES LICENSING OF NATESTO® IN 19 CENTRAL AND LATIN AMERICAN COUNTRIES \n* SIGNING OF AGREEMENT GRANTING PRODUCTO CIENTÍFICOS EXCLUSIVE RIGHT TO MARKET NATESTO IN 19 CENTRAL AND LATIN AMERICAN COUNTRIES \n* UNDER TERMS, WILL RECEIVE UPFRONT FEE, REGULATORY MILESTONE PAYMENTS UPON CARNOT LABORATORIOS RECEIVING MARKETING APPROVAL IN TERRITORY \n* IN ADDITION, ACERUS WILL RECEIVE A SUPPLY PRICE FOR PRODUCT Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-13T14:14:00.000+03:00", "crawled": "2018-04-13T14:24:43.000+03:00", "highlightTitle": ""}